Kinfo
Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Inc.

EPRXNASDAQHealthcare·US · USD
$8.15
+0.34 (+4.35%)
Prices as of November 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap548.24M USD
Enterprise value454.54M USD
Trailing P/E-7.92
Forward P/E-7.99
PEG ratio0.69
Price / sales0.00
Price / book5.99
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-36.57%
Return on equity-56.44%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-65.98M USD
Net income-61.62M USD
Diluted EPS-$1.02
Rev. growth (YoY)0.00%
Balance sheet
Total cash126.42M USD
Total debt3.42M USD
Debt / equity2.83
Current ratio12.25
Book value / share$1.36
Cash flow (TTM)
Operating cash flow-44.30M USD
Levered free cash flow-27.81M USD
Shares & price
Shares outstanding65.74M
Float56.80M
Held by institutions41.53%
Beta0.00
50-day MA$7.64
200-day MA$7.23
52-week high$9.32
52-week low$5.63
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-10-0.26-0.23+11.54%2026-08-11-0.23-0.23+0.00%2026-07-291.191.35+13.45%2026-07-153.142.81−10.51%2026-06-10-0.77-1.36−76.62%
About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing locally delivered, extended-release therapies designed to improve how medicines act within targeted tissues. The company’s work centers on its proprietary DiffuSphere delivery platform, which is used to reformulate existing and novel drugs for controlled release in the right place over an extended period. Eupraxia Pharmaceuticals Inc. is advancing product candidates for conditions with significant unmet medical need, including inflammatory and pain-related disorders, eosinophilic esophagitis, and other localized therapeutic areas. Its current business is built around drug delivery technology, clinical development, and intellectual property, positioning the company within the biotechnology and specialty pharmaceuticals sectors. Headquartered in Victoria, British Columbia, Canada, Eupraxia Pharmaceuticals Inc. focuses on improving local treatment performance while limiting broader systemic exposure.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. James A. Helliwell FRCPC, M.D.
Employees
49
Headquarters
Victoria, BC, Canada

Frequently asked questions about Eupraxia Pharmaceuticals Inc.